Tempus IVDR win bolsters European reach but does not resolve core WAIT concerns

What happened

Tempus AI announced IVDR certification for its xR RNA sequencing assay as a Class C in vitro diagnostic device, covering next-generation sequencing for cancer genomic profiling. This regulatory milestone expands market access in the EU and adds to the company's regulatory moat, complementing existing FDA approvals. However, the latest DeepValue master report maintains a WAIT rating at $44.3, reflecting that the stock already embeds strong Diagnostics and Data momentum. The certification does not address the two primary uncertainties: proof that the planned $1.5B Personalis acquisition will not reset the margin timeline, and sustained conversion of signed Data and Applications licenses into revenue. As such, the news is a small positive but does not alter the near-term risk/reward.

Implication

Investors should treat the IVDR certification as a low-impact positive that bolsters Tempus's regulatory credibility in Europe but does not change the investment thesis. The key questions remain whether Data and Applications growth persists above 28% and whether the Personalis acquisition closes without new debt or diluted EBITDA guidance. The stock at $44.3 is near the DeepValue trim level of $52 and above the attractive entry of $38, so risk/reward is not compelling. A post-deal earnings print with clean metrics could warrant reassessment, while a break below $38 on execution missteps would offer a better entry. Until then, the WAIT rating stands.

Thesis delta

No material thesis shift. The IVDR certification reinforces the company's regulatory moat in oncology diagnostics but does not address the dominant uncertainties around Personalis integration, Data and Applications conversion, and GAAP profitability. The WAIT rating remains appropriate.